Klaria Interim Report Q3 2021
Summary of the interim reportPromising quarter with registration applications and preparations for additional clinical studies THIRD QUARTER OF 2021 · Net sales amounted to 0.0 MSEK (0.0 MSEK) · Other income amounted to 0.0 MSEK (3.4 MSEK) · R&D costs for the period amounted to 12.5 MSEK (13.6 MSEK) · Profit after tax amounted to -15.2 MSEK (-13.3 MSEK) · Earnings per share for the quarter amounted to -0.29 SEK (-0.28 SEK) · Cash flow from operating activities amounted to -13.7 MSEK (-12.2 MSEK) · Cash and cash equivalents on the balance sheet date amounted to 25.9